Summary: In this placebo-controlled trial, 6609 patients with chronic kidney disease at risk of progression received empagliflozin 10 mg daily or placebo. Over a median of 2.0 years, kidney disease progression or cardiovascular death occurred in 13.1% against 16.9% (hazard ratio 0.72; 95% CI 0.64 to 0.82), consistent with or without diabetes, while all-cause death and heart failure hospitalisation or cardiovascular death did not differ significantly.
PICO Summary
| Element | Detail |
|---|---|
| Population | 6609 patients with chronic kidney disease: eGFR 20 to under 45 mL/min/1.73 m², or eGFR 45 to under 90 with urinary albumin-to-creatinine ratio of at least 200; with or without diabetes; randomised, placebo-controlled (EMPA-KIDNEY). |
| Intervention | Empagliflozin 10 mg once daily (n=3304); median follow-up 2.0 years. |
| Comparison | Matching placebo (n=3305). |
| Outcome | Kidney disease progression or cardiovascular death: 432 (13.1%) vs 558 (16.9%); HR 0.72 (95% CI 0.64-0.82); p<0.001. Hospitalisation from any cause: HR 0.86 (95% CI 0.78-0.95); p=0.003. Heart failure hospitalisation or cardiovascular death 4.0% vs 4.6% and death from any cause 4.5% vs 5.1% (no significant differences). Serious adverse events similar. |
Expert Commentary
My verdict is positive. This large, placebo-controlled trial enrolled 6609 patients with chronic kidney disease at risk of progression, with or without diabetes, and the primary composite of kidney disease progression or cardiovascular death occurred in 13.1% on empagliflozin and 16.9% on placebo over a median of 2.0 years (hazard ratio 0.72; 95% CI 0.64 to 0.82). Results were consistent with or without diabetes and across eGFR ranges, which is reassuring for a broad inclusion strategy. Hospitalisation from any cause was lower (hazard ratio 0.86; 95% CI 0.78 to 0.95), whereas heart failure hospitalisation or cardiovascular death (4.0% against 4.6%) and all-cause death (4.5% against 5.1%) did not differ significantly. The limitation is that the abstract does not break the primary composite into its components, so I cannot say how much of the effect arises from kidney progression alone; follow-up was also short at 2.0 years. Funding came from Boehringer Ingelheim and others. Can I use this with my patients? Yes, for patients with an eGFR of at least 20 but under 45, or an eGFR of at least 45 but under 90 with a urinary albumin-to-creatinine ratio of at least 200, whether or not they have diabetes. Component-level and longer-term results should be published in full detail.
References
The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233. PMID: 36331190.

